Literature DB >> 9014927

The treatment of acute leukaemia.

A K Burnett1, O B Eden.   

Abstract

Developments in supportive care, new regimens for induction of remission and consolidation therapy, and bone-marrow transplantation have improved the outlook for patients with acute leukaemia. The outlook, though, is influenced by age and factors related to the biology of the disease. In acute myeloid leukaemia age is such an important factor that it determines approach to therapy. Overcoming resistance to chemotherapy is an area that needs much attention.

Entities:  

Mesh:

Year:  1997        PMID: 9014927     DOI: 10.1016/s0140-6736(96)08086-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  4 in total

Review 1.  Chemotherapy for cancer patients who present late.

Authors:  Stella J Bowcock; Charles D Shee; Saad M B Rassam; Peter G Harper
Journal:  BMJ       Date:  2004-06-12

Review 2.  Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer.

Authors:  M M Buckley; H M Lamb
Journal:  Drugs Aging       Date:  1997-07       Impact factor: 3.923

Review 3.  Bone marrow transplantation using unrelated donors for haematological malignancies.

Authors:  O Ringdén
Journal:  Med Oncol       Date:  1997-03       Impact factor: 3.064

4.  Gene therapy that inhibits NF-kappaB results in apoptosis of human hepatocarcinoma by recombinant adenovirus.

Authors:  Tie-Jun Li; Li-Ping Jia; Xiao-Ling Gao; Ai-Long Huang
Journal:  World J Gastroenterol       Date:  2006-09-07       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.